期刊文献+

卵巢癌术后化疗联合醋酸甲羟孕酮抑制盆腔病理血管生成分析

Chemotherapy Combined With Postoperative Chemotherapy Combined With Progesterone Acetate in the Treatment of Ovarian Cancer
下载PDF
导出
摘要 目的研究卵巢癌术后化疗联合醋酸甲羟孕酮抑制盆腔病理血管生成分析。方法收取我院60例卵巢癌患者,分为两组,观察组采用化疗联合醋酸甲羟孕酮,对照组采用化疗。结果观察组Ⅲ/Ⅱ期患者病理血管分支10支与对照组Ⅲ/Ⅱ期患者病理血管分支16支相比,差异有统计学意义,P<0.05,手术后1年,观察组患者病理血管分支少于对照组,P<0.05,观察组患者生存率、1年生存率90.00%高于对照组,P<0.05。结论卵巢癌术后化疗联合醋酸甲羟孕酮能有效抑制盆腔病理血管的生成。 Objective To study the effects of chemotherapy combined with Progesterone Acetate in the treatment of ovarian cancer after surgical treatment of pelvic pathological blood vessel formation. Methods 60 cases of ovarian cancer in our hospital were divided into two groups,the observation group was treated with chemotherapy combined with acetic acid,the control group was treated with chemotherapy. Results Observation group III / II patients with pathological blood vessel branch 10 and control group III / II patients with pathological blood vessel branch 16 compared,the difference was statistically significant,P〈0.05,1 years after the surgery,the observation group of patients with pathological vascular branches less than the control group,P〈0.05,the survival rate of patients in the observation group,1 year survival rate was 90% higher than the control group,P〈0.05. Conclusion Chemotherapy combined with Progesterone Acetate after ovarian cancer surgery can effectively inhibit the formation of pathological blood vessels in the pelvis.
作者 杨磊
出处 《中国卫生标准管理》 2016年第21期151-152,共2页 China Health Standard Management
关键词 化疗 卵巢癌 醋酸甲羟孕酮 Chemotherapy Ophoroma Progesterone acetate
  • 相关文献

参考文献8

二级参考文献28

  • 1Christen L Walters Haygood,Rebecca C Arend,J Michael Straughn,Donald J Buchsbaum.Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?[J].World Journal of Stem Cells,2014,6(4):441-447. 被引量:7
  • 2段庚仙.恶性肿瘤化疗的毒副作用及其防治[J].肿瘤研究与临床,2004,16(5):353-354. 被引量:37
  • 3Zhang XM, Ming-Tat L, Xianghong W,et al. Inactivation of ld-1 in prostate cancer cells : A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway [ J ]. lnt J Cancer, 2006,118 ( 8 ) :2072 - 2081.
  • 4Basdevant A,Bringer J,Lefebvre P.Weight,nutrition and hormonal events in women.Hum Reprod,1997,12(Suppl 1):73-74
  • 5Shuldiner AR,Yang R,Gong DW. Resistin,obesity and insulin resistance-the emerging role of the adipocyte as an endocrine organ.N Engl J Med,2001,345(18):1345-1346
  • 6Steppan CM,Bailey ST,Bhat S,et al.The hormone resistin links obesity to diabetes.Nature,2001,409:307-312
  • 7Burana-Osot J, Ungboriboonpisal S, Sriphong L. A stability- indicating HPLC method for medroxyprogesterone acetate in bulk drug and injection formulation [J]. J Pharm Biomed Anal, 2006, 40 (5): 1068-1072.
  • 8chemotherapy with carboplatin and docetaxel in advanced ovarian cancer aprospectivem uki- center phase trial(PRIMOVAR) [ J]. Oncol Rep,2009,22 (3) :605 - 613.
  • 9Dressel R, Grzeszik C, Kreiss M, et al. Differ- ential effect of acute and permanent heat shock protein 70 over expression in tumor cells on ly- sability by eytotoxic T lymphocytes[ J ]. Cancer Res,2003,63 (23) : 8212 - 8220.
  • 10Rafii A, Deval B, Geay JF, et al. Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoad- juvantc hemotherapy: ar etrospective study [ J ]. Int J Gynecol Cancer, 2007,17 (4) : 777 - 783.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部